Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction chemotherapy followed by concurrent PD-1 inhibitor, anlotinib, and radiotherapy for locally advanced esophageal squamous cell carcinoma
ChiCTR2200056920Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and PD-1 Monoclonal Antibody in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 2-year event-free survival. Started Jan 2022; status: recruiting.
02
Drugs
anlotinibPD-1 Monoclonal Antibody
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2200056920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056920.